Announcement on the consistency evaluation of subsidiary drugs through generic drugs.
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2020-002
Zhejiang Jianfeng Group Co., Ltd.
Announcement
on Compliance Evaluation of Subsidiary Drugs Passing Generic Drugs The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Company " ), a controlling subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "" Jianfeng Pharmaceutical "), received the" Drug Supplementary Application Approval "for paroxetine hydrochloride tablets approved and issued by the State Drug Administration (batch number: 2020B02472 ), Jianfeng Pharmaceutical Paroxetine Hydrochloride Tablets have passed the consistency evaluation of generic drug quality and curative effect (hereinafter referred to as" generic drug consistency evaluation "). The relevant information is hereby announced as follows:
1. Drug Basic Information
Drug Name: Paroxetine Hydrochloride Tablets
Dosage Form: Tablet
Specification: 20mg (calculated by C 19 H 20 FNO 3 )
Registration Classification: Chemical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Acceptance No.: CYHB1950106
Batch No.: 2020B02472
Approval Conclusion: according to the provisions of the the People's Republic of China Drug Administration Law, the Opinions of the State Council on Reforming the Review and Approval System for Drugs and Medical Devices (Guo Fa (2015 ) 44 ) and the Announcement on Matters Related to the Evaluation of Quality and Efficacy Consistency of Generic Drugs (2017 100 ), after examination, this product has passed the evaluation of quality and efficacy consistency of generic drugs.
OTHER CONDITIONS RELATED TO 2. MEDICINE
(I) FUNCTION INDICATIONS: This product is used to treat depression, obsessive compulsive disorder, panic disorder with or without square terrors, social phobia/ social anxiety disorder. After the curative effect is satisfied, continue to take this product can prevent the recurrence of depression, panic disorder and obsessive-compulsive disorder.
(II) The National Drug Administration received the application for consistency evaluation of the drug in January of 2019 1 .
(III) As of the date of disclosure of this report, the drug research and development investment of about 1289 yuan (unaudited).
(IV) Included in the National Medical Insurance and Basic Drug List: Paroxetine Hydrochloride Tablets have been included in the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug List (2019 Edition ) and classified as Class A; It has been listed in the National Essential Drug List (2018 Edition ) .
(V) the market situation of similar drugs: domestic enterprises that have passed the consistency evaluation of this drug are: Zhejiang Huahai Pharmaceutical Co., Ltd., Beijing Fuyuan Pharmaceutical Co., Ltd., and Sino-US Tianjin SmithKline Pharmaceutical Co., Ltd. In 2018 , the sales of paroxetine hydrochloride tablets in domestic hospitals were about 3.78 .8 billion yuan (data from the database of drug intelligence network). In 2018 , Jianfeng Pharmaceutical achieved a cumulative sales of paroxetine hydrochloride tablets of about 9739.49 yuan.
3. Risk Alert
According to relevant national policies, drug varieties that pass the consistency evaluation will receive greater support in the fields of medical insurance payment and medical institution procurement. If there are more than 3 manufacturers of the same variety of drugs that pass the consistency evaluation of generic drugs, the varieties that do not pass the consistency evaluation of generic drugs will no longer be selected in the centralized procurement of drugs. The Paroxetine Hydrochloride Tablets of Jianfeng Pharmaceuticals has passed the quality and efficacy consistency evaluation of generic drugs, which is conducive to expanding the market share of the drug and enhancing its market competitiveness. As drug sales are affected by national policies, market environment and other factors, there is greater uncertainty. Investors are advised to pay attention to investment risks.
is hereby announced.
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
March 11, 2020
More information
On the afternoon of June 9, Peak Cable Company organized all employees to learn fire fighting knowledge and conducted fire fighting and emergency escape drills. Since June, the subordinate enterprises of the company have organized training, learning and drills related to production safety according to their own characteristics and combined with the actual work. Safety production month series of activities carried out in an orderly manner.
2022
06-13
Spike Postdoctoral Research Papers on International Frontier Journals
Recently, good news came from the postdoctoral workstation of Jianfeng Pharmaceutical. Under the guidance of workstation mentor Jiang Xiaomeng, associate researcher Yang Xiaoxiao has made new progress in the treatment of alcoholic liver disease. The relevant research results "Roxadustat, a hypoxia-inducible factor 1a activator, attenuates both long- and short-term alcohol induced alcoholic liver disease" were published in the internationally renowned academic journal "Frontiers in Pharmacology. This journal is a frontier journal in the field of international pharmacy, mainly publishing academic papers and information on basic and clinical pharmacology, medicinal chemistry, pharmacology and toxicology.
2022
06-01
Daye Peak QC Achievements Won the Third Prize of Huangshi City
On May 7, Huangshi City Quality Strong City Working Committee organized a 2022 QC Results Conference. The QC project of "Technical Transformation of Ore Limestone Batching System" of Daye Peak Cement Company won the third prize.
2022
06-01
On April 28, Dalian Commodity Exchange held an online working meeting to announce the results of the 2021 excellent delivery warehouse and delivery warehouse excellent futures personnel selection, peak international trading company won the 2021 "excellent designated delivery warehouse" title, futures commissioner Ruan Weihang won the "excellent futures personnel" title.
2022
06-01
Cranberry extract combination identification detection method won the invention patent
After cranberry extract products were included in the "Zhejiang Province Key High-tech Product Development Project Plan" in 2021, Jianfeng Health Technology Company recently obtained an invention patent for the identification and detection method of cranberry extract. This new combined identification and detection method developed by Jianfeng Health identifies whether catechin or procyanidin B2 is added in cranberry extract by thin layer analysis, and then detects the unique A- type procyanidin and its chromatographic distribution in cranberry extract by high performance liquid chromatography, so as to improve the accuracy of product judgment. The identification method has the characteristics of accurate results and short detection time, which is of great significance to standardize the cranberry extract market and promote the healthy development of the industry, and has been unanimously recognized by peers.
2022
05-20
Daye Peak Manufacturing Department Won the Title of "Worker Pioneer" in Hubei Province
A few days ago, the manufacturing department of Daye Peak Cement Company was awarded the title of "Worker Pioneer" by the Hubei Provincial Federation of Trade Unions. Daye Jianfeng Manufacturing Department not only continued to actively explore and achieved good results in energy saving and consumption reduction, technological transformation, product quality process control, and economic responsibility system to guide management, but also improved Daye Jianfeng's overall operation level and won Huangshi City The seventh "Mayor Quality Award" created conditions and was fully affirmed by government departments at all levels.
2022
05-20
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page